Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.51 USD | -8.53% | +140.60% | +120.93% |
Mar. 15 | Arcadium Lithium says Argentina operation not affected by court ban | RE |
Mar. 15 | Arcadium says Fenix and Sal de Vida projects unaffected by Argentina court ruling | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 14.67 for the current year.
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 4.92 times its current sales, is high.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+120.93% | 6.56B | B+ | ||
+16.09% | 66.26B | A- | ||
-1.86% | 47.33B | A- | ||
+15.27% | 40.92B | B+ | ||
+1.62% | 17.76B | C+ | ||
+11.35% | 16.58B | B+ | ||
-10.04% | 15.14B | C+ | ||
+30.57% | 13.41B | A- | ||
-0.95% | 9.3B | A | ||
-2.93% | 8.55B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Arcadium Lithium plc
- Stock LIVENT - Nyse
- Ratings LIVENT